Glycation in Parkinson's disease and Alzheimer's disease

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 782-790

  Vicente Miranda, Hugo ^a   El Agnaf, Omar M A ^b   Outeiro, Tiago Fleming ^a,c,d  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Alzheimer's disease; Glycation; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; METFORMIN;

AGE; ALZHEIMER DISEASE; ANXIETY DISORDER; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; ENZYME ACTIVITY; HUMAN; HYPERGLYCEMIA; HYPOSMIA; LEWY BODY; NERVE DEGENERATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PSYCHOSIS; REVIEW; RISK FACTOR; SLEEP DISORDER; ANIMAL; METABOLISM;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; PARKINSON DISEASE;

EID: 84959455993     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26566     Document Type: Review

References (140)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813-820.
2. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251(2):87-101.
3. Maillard L. Action des acides amines sur les sucre: formation des melanoidines par voie methodique. C R Hebd Seances Acad Sci 1912;154:66-68.
4. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nature clinical practice Endocrinol Metab 2008;4(5):285-293.
5. Thornalley PJ. Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci 2005;1043:111-117.
6. Phillips SA, Thornalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 1993;212(1):101-105.
7. Richard JP. Acid-base catalysis of the elimination and isomerization reactions of triose phosphates. J Am Chem Soc 1984;106(17):4926-4936.
8. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem J 2002;364(Pt 1):1-14.
9. Ahmed N, Thornalley PJ. Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J 2002;364(Pt 1):15-24.
10. Oya T, Hattori N, Mizuno Y, et al. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 1999;274(26):18492-18502.
11. Shipanova IN, Glomb MA, Nagaraj RH. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch Biochem Biophys 1997;344(1):29-36.
12. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997;324 (Pt 2):565-570.
13. Frye EB, Degenhardt TP, Thorpe SR, Baynes JW. Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 1998;273(30):18714-18719.
14. Rabbani N, Thornalley PJ. Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochem Soc Trans 2008;36(Pt 5):1045-1050.
15. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344 Pt 1:109-116.
16. Sousa Silva M, Gomes RA, Ferreira AE, Ponces Freire A, Cordeiro C. The glyoxalase pathway: the first hundred years... and beyond. Biochem J 2013;453(1):1-15.
17. Monder C. Alpha-keto aldehyde dehydrogenase, an enzyme that catalyzes the enzymic oxidation of methylglyoxal to pyruvate. J Biol Chem 1967;242(20):4603-4609.
18. Vander Jagt DL, Robinson B, Taylor KK, Hunsaker LA. Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. J Biol Chem 1992;267(7):4364-4369.
19. Izaguirre G, Kikonyogo A, Pietruszko R. Methylglyoxal as substrate and inhibitor of human aldehyde dehydrogenase: comparison of kinetic properties among the three isozymes. Comp Biochem Physiol B Biochem Mol Biol 1998;119(4):747-754.
20. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014;24(10):R453-462.
21. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Thorpe SR. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 1996;11(Suppl 5):48-53.
22. Schleicher E, Wieland OH. Kinetic analysis of glycation as a tool for assessing the half-life of proteins. Biochim Biophys Act 1986;884(1):199-205.
23. Watkins NG, Neglia-Fisher CI, Dyer DG, Thorpe SR, Baynes JW. Effect of phosphate on the kinetics and specificity of glycation of protein. J Biol Chem 1987;262(15):7207-7212.
24. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29(13):1583-1590.
25. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.
26. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 1998;95(11):6469-6473.
27. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274(5290):1197-1199.
28. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55(3):259-272.
29. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical E. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5(3):235-245.
30. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1(1):a006189.
31. Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis 2013;33(Suppl 1):S123-139.
32. Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 2010;19(1):311-323.
33. Koehler NK, Stransky E, Shing M, et al. Altered serum IgG levels to alpha-synuclein in dementia with Lewy bodies and Alzheimer's disease. PLoS One 2013;8(5):e64649.
34. Mattsson N, Insel P, Tosun D, et al. Effects of baseline CSF alpha-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. PLoS One 2013;8(12):e85443.
35. Yang F, Ueda K, Chen P, Ashe KH, Cole GM. Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res 2000;853(2):381-383.
36. Korff A, Liu C, Ginghina C, Shi M, Zhang J, Alzheimer's Disease Neuroimaging I. alpha-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis 2013;36(4):679-688.
37. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70(10):1277-1287.
38. Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2012;2(1):a008888.
39. Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 2007;86(5):1486-1494.
40. Perrone L, Grant WB. Observational and ecological studies of dietary advanced glycation end products in national diets and Alzheimer's disease incidence and prevalence. J Alzheimers Dis 2015;45(3):965-979.
41. Schwab RS. Progression and prognosis in Parkinson's disease. J Nerv Ment Dis 1960;130:556-566.
42. Barbeau A, Giguere R, Hardy J. [Clinical experience with tolbutamide in Parkinson's disease]. Union Med Can 1961;90:147-151.
43. Lipman IJ, Boykin ME, Flora RE. Glucose intolerance in Parkinson's disease. J Chron Dis 1974;27(11-12):573-579.
44. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 1993;69(1-4):125-130.
45. Boyd AE, 3rd, Lebovitz HE, Feldman JM. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-dopa. J Clin Endocrinol Metab 1971;33(5):829-837.
46. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007;30(4):842-847.
47. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011;34(4):910-915.
48. Arvanitakis Z, Wilson RS, Bienias JL, Bennett DA. Diabetes and parkinsonian signs in older persons. Alzheimer Dis Assoc Disord 2007;21(2):144-149.
49. Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: A case-control study. Neurology 2012;78(19):1507-1511.
50. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care 2008;31(9):1808-1812.
51. Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care 2011;34(12):2614-2623.
52. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008;31(10):2003-2005.
53. Lu L, Fu DL, Li HQ, Liu AJ, Li JH, Zheng GQ. Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS One 2014;9(1):e85781.
54. Uchiki T, Weikel KA, Jiao W, et al. Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics). Aging Cell 2012;11(1):1-13.
55. Ikemoto S, Takahashi M, Tsunoda N, Maruyama K, Itakura H, Ezaki O. High-fat diet-induced hyperglycemia and obesity in mice: differential effects of dietary oils. Metab Clin Exp 1996;45(12):1539-1546.
56. Ikemoto S, Thompson KS, Takahashi M, Itakura H, Lane MD, Ezaki O. High fat diet-induced hyperglycemia: prevention by low level expression of a glucose transporter (GLUT4) minigene in transgenic mice. Proc Natl Acad Sci U S A 1995;92(8):3096-3099.
57. Morris JK, Bomhoff GL, Stanford JA, Geiger PC. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 2010;299(4):R1082-1090.
58. Choi JY, Jang EH, Park CS, Kang JH. Enhanced susceptibility to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic Biol Med 2005;38(6):806-816.
59. Rotermund C, Truckenmuller FM, Schell H, Kahle PJ. Diet-induced obesity accelerates the onset of terminal phenotypes in alpha-synuclein transgenic mice. J Neurochem 2014;131(6):848-858.
60. Han Y, Randell E, Vasdev S, et al. Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with Type 1 diabetes. Mol Cell Biochem 2007;305(1-2):123-131.
61. McLellan AC, Thornalley PJ, Benn J, Sonksen PH. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sc 1994;87(1):21-29.
62. Wang H, Meng QH, Gordon JR, Khandwala H, Wu L. Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus. Clin Biochem 2007;40(16-17):1232-1239.
63. Dhar I, Dhar A, Wu L, Desai KM. Increased methylglyoxal formation with upregulation of renin angiotensin system in fructose fed Sprague Dawley rats. PLoS One 2013;8(9):e74212.
64. Wang X, Desai K, Chang T, Wu L. Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 2005;23(8):1565-1573.
65. Wang X, Jia X, Chang T, Desai K, Wu L. Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats. J Hypertens 2008;26(4):765-772.
66. Li W, Maloney RE, Aw TY. High glucose, glucose fluctuation and carbonyl stress enhance brain microvascular endothelial barrier dysfunction: Implications for diabetic cerebral microvasculature. Redox Biol 2015;5:80-90.
67. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996;737(1-2):195-200.
68. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 2005;64(9):816-830.
69. Munch G, Luth HJ, Wong A, et al. Crosslinking of alpha-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation? J Chem Neuroanat 2000;20(3-4):253-257.
70. Choi YG, Lim S. N(varepsilon)-(carboxymethyl)lysine linkage to alpha-synuclein and involvement of advanced glycation end products in alpha-synuclein deposits in an MPTP-intoxicated mouse model. Biochimie 2010;92(10):1379-1386.
71. Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 2008;86(9):2071-2082.
72. Lee D, Park CW, Paik SR, Choi KY. The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim Biophys Act 2009;1794(3):421-430.
73. Guerrero E, Vasudevaraju P, Hegde ML, Britton GB, Rao KS. Recent advances in alpha-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease. Mol Neurobiol 2013;47(2):525-536.
74. Outeiro TF, Kazantsev A. Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies. Perspect Medic Chem 2008;2:41-49.
75. Outeiro TF, Putcha P, Tetzlaff JE, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008;3(4):e1867.
76. Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 2011;108(10):4194-4199.
77. Kurz A, Rabbani N, Walter M, et al. Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell Mol Life Sci 2011;68(4):721-733.
78. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Inter 1998;111-112:137-151.
79. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Act Neurol Scand Suppl 1993;146:6-13.
80. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36(3):348-355.
81. Kuhla B, Boeck K, Luth HJ, et al. Age-dependent changes of glyoxalase I expression in human brain. Neurobiol Aging 2006;27(6):815-822.
82. Chen L, Thiruchelvam MJ, Madura K, Richfield EK. Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol Dis 2006;23(1):120-126.
83. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001;10(9):919-926.
84. Im JY, Lee KW, Woo JM, Junn E, Mouradian MM. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum Mol Genet 2012;21(13):3013-3024.
85. Xue M, Rabbani N, Momiji H, et al. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J 2012;443(1):213-222.
86. Lee JY, Song J, Kwon K, et al. Human DJ-1 and its homologs are novel glyoxalases. Hum Mol Genet 2012;21(14):3215-3225.
87. Richarme G, Mihoub M, Dairou J, Bui LC, Leger T, Lamouri A. Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues. J Biol Chem 2015;290(3):1885-1897.
88. Beisswenger PJ, Howell SK, Smith K, Szwergold BS. Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Act 2003;1637(1):98-106.
89. Liu L, Xiong N, Zhang P, et al. Genetic variants in GAPDH confer susceptibility to sporadic Parkinson's disease in a Chinese Han population. PLoS One 2015;10(8):e0135425.
90. Deng Y, Zhang Y, Li Y, et al. Occurrence and distribution of salsolinol-like compound, 1-acetyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains. J Neural Transm 2012;119(4):435-441.
91. Song DW, Xin N, Xie BJ, et al. Formation of a salsolinol-like compound, the neurotoxin, 1-acetyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes. Int J Mol Med 2014;33(3):736-742.
92. Xie B, Lin F, Ullah K, et al. A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease. Biochem Biophys Res Commun 2015;459(3):361-366.
93. Vagelatos NT, Eslick GD. Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 2013;35:152-160.
94. Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F, Scheltens P. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 2006;77(3):304-307.
95. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010;31(2):224-243.
96. Trudeau F, Gagnon S, Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur J Pharmacol 2004;490(1-3):177-186.
97. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38.
98. Carvalho C, Cardoso S, Correia SC, et al. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes 2012;61(5):1234-1242.
99. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994;91(11):4766-4770.
100. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994;91(12):5710-5714.
101. Faure P, Troncy L, Lecomte M, et al. Albumin antioxidant capacity is modified by methylglyoxal. Diabetes Metab 2005;31(2):169-177.
102. Kimura T, Takamatsu J, Araki N, et al. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport 1995;6(6):866-868.
103. Ledesma MD, Bonay P, Avila J. Tau protein from Alzheimer's disease patients is glycated at its tubulin-binding domain. J Neurochem 1995;65(4):1658-1664.
104. Chen K, Maley J, Yu PH. Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem 2006;99(5):1413-1424.
105. Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 1994;269(34):21614-21619.
106. Munch G, Mayer S, Michaelis J, et al. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Act 1997;1360(1):17-29.
107. Necula M, Kuret J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem 2004;279(48):49694-49703.
108. Woltjer RL, Maezawa I, Ou JJ, Montine KS, Montine TJ. Advanced glycation endproduct precursor alters intracellular amyloid-beta/A beta PP carboxy-terminal fragment aggregation and cytotoxicity. J Alzheimers Dis 2003;5(6):467-476.
109. Ko SY, Lin YP, Lin YS, Chang SS. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 2010;49(3):474-480.
110. Liu BF, Miyata S, Hirota Y, et al. Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int 2003;63(3):947-957.
111. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 2000;74(4):1587-1595.
112. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 2000;59(10):880-888.
113. Luth HJ, Ogunlade V, Kuhla B, et al. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex 2005;15(2):211-220.
114. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2005;92(2):255-263.
115. Bar KJ, Franke S, Wenda B, et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 2003;24(2):333-338.
116. Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 2001;22(3):397-402.
117. Li XH, Du LL, Cheng XS, et al. Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell Death Dis 2013;4:e673.
118. Labuzek K, Liber S, Gabryel B, Okopien B. Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol Rep 2010;62(5):827-848.
119. Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010;62(5):956-965.
120. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord 2012;18(6):753-758.
121. Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 2011;24(3):485-493.
122. Kickstein E, Krauss S, Thornhill P, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 2010;107(50):21830-21835.
123. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011;60(6):910-920.
124. Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience 2014;277:747-754.
125. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003;29(4 Pt 2):6S95-103.
126. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Hormone Metab Res 2012;44(12):891-895.
127. Schurman L, McCarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008;116(6):333-340.
128. Puddu A, Mach F, Nencioni A, Viviani GL, Montecucco F. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflamm 2013;2013:591056.
129. Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol 2009;202(3):431-439.
130. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism. Proc Natl Acad Sci U S A 2009;106(4):1285-1290.
131. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013;123(6):2730-2736.
132. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 2014;4(3):337-344.
133. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011;31(17):6587-6594.
134. Xu W, Yang Y, Yuan G, Zhu W, Ma D, Hu S. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. J Invest Med 2015;63(2):267-272.
135. Solmaz V, Cinar BP, Yigitturk G, Cavusoglu T, Taskiran D, Erbas O. Exenatide reduces TNF-alpha expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur J Pharmacol 2015;765:482-487.
136. Patrone C, Eriksson O, Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014;2(3):256-262.
137. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010;5(2):109-117.
138. Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clinical Trials 1999;20(5):493-510.
139. Chinchansure AA, Korwar AM, Kulkarni MJ, Joshi SP. Recent development of plant products with anti-glycation activity: a review. RSC Advances 2015;5(39):31113-31138.
140. Vicente Miranda H, Outeiro TF. The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 2010;221(1):13-25.